Israeli pharmaceutical giant Teva has agreed to establish a joint venture with South Korean pharmaceutical company Handok. Teva will have a 51 percent stake in the venture, and will be in charge of manufacturing and supplying medicine. Handok will market, sell and distribute the products. The South Korean pharmaceutical market is estimated to be worth $14 billion.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
UK Adopts Israeli Counter-Drone Technology
April 25, 2024
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments